All Blogs
Oct 31, 2023
Phase III RUBY Trial of Jemperli Plus Chemotherapy Updates; FDA Approves Roche’s Vabysmo for RVO; FDA Grants Priority Review to Tovorafenib Low-Grade Glioma; FDA Approves Lilly’s Omvoh; FDA Approves Toripalimab for Nasopharyngeal Carcinoma; FDA Fast Track Designation to ONCT-534 R/R mCRPC
FDA Granted Fast Track Designation to Oncternal Therapeutics’s ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer On Oct. 26, 2023, Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting andr...
Read More...
Oct 30, 2023
Rare but Real: Unraveling the Different Types of Bone Sarcoma
Bone sarcoma is a rare and aggressive form of cancer that develops in bone tissue. The likelihood of a person being diagnosed with primary bone sarcoma and their recovery prospects depend on various unique factors. In 2023, it is expected that 4,000 individuals across all age groups in the United States will receiv...
Read More...
Oct 27, 2023
AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure
Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around 3 in 100 individuals with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The...
Read More...
Oct 26, 2023
Cardio Flow’s FreedomFlow Orbital Atherectomy Peripheral Platform; Medtronic’s Aurora EV- ICD System to Treat Arrhythmias; GE Healthcare and Novo Nordisk Announces Collaboration; Olympus’s EVIS X1 Endoscopy System; Medtronic’s Evolut TAVR Platform Outperformed Surgery with Sustained Valve Performance; Abbott’s Minimally Invasive Devices for People with Leaky Heart Valves
Olympus Announced Market Launch of EVIS X1™ Endoscopy System On October 19, 2023, Olympus Corporation, a global medical technology company announced the market launch of its next-generation EVIS X1™ endoscopy system. The GIF-1100 gastrointestinal videoscope indicated for use in the upper digestive tract, and ...
Read More...
Oct 25, 2023
Charting the Growth of the Insulin Pens Market Amidst Rising Demand
The evolution of technology has been a driving force behind the remarkable growth of the Insulin Pens market. Insulin Pens, from their inception as relatively basic delivery devices, have undergone a substantial transformation, becoming highly advanced and user-friendly tools. In the early stages, these pens requir...
Read More...
Oct 24, 2023
FDA Approves PENBRAYA for Most Common Serogroups Causing Meningococcal Disease; BIMZELX Approved Moderate to Severe Plaque Psoriasis; FDA Approves BioMarin’s VOXZOGO; FDA Fast Track Designation to ANPD001 for Parkinson’s Disease; UCB Announces FDA Approval of ZILBRYSQ; EMA Granted Orphan Drug Designation to Lisata’s LSTA1
UCB announces FDA approval of ZILBRYSQ for the Treatment of Adults with Generalized Myasthenia Gravis On the 17th of October 2023, UCB (Euronext Brussels: UCB) made an announcement regarding the approval of ZILBRYSQ® (zilucoplan) by the US FDA for the management of generalized myasthenia gravis (gMG) in adult pa...
Read More...
Oct 23, 2023
Ardelyx Overcomes Hurdles to Secure FDA Approval for Xphozah in Chronic Kidney Disease Treatment
Ardelyx has struck gold on its third attempt with Xphozah (tenapanor), the chronic kidney disease medication. Following two prior rejections, the FDA has granted its long-awaited approval. Xphozah, an innovative phosphate absorption inhibitor, is now officially sanctioned for the management of serum phosphate level...
Read More...
Oct 20, 2023
New Player in Ulcerative Colitis Treatment: Pfizer’s Etrasimod Entry Counters BMS’ Zeposia
Bristol Myers Squibb’s Zeposia has lost its exclusive status as the sole S1P receptor modulator available for ulcerative colitis treatment. The FDA has granted approval for Pfizer’s ulcerative colitis medication, Etrasimod, under the brand name Velsipity. This decision comes after the publication of Phase III resul...
Read More...
Oct 19, 2023
Mindray Collaborated with Edwards Lifesciences; DuPont’s Low-Cyclics Silicone Soft Skin Adhesive; GE HealthCare’s Allia IGS Pulse; Praxis Medical’s EndoCore EBUS-TBNA Biopsy Device; Visioneering’s PROTECT Clinical Trial; SynerFuse’s e-TLIF procedure
DuPont Launched Higher-Adhesion and Low-Cyclics Silicone Soft Skin Adhesive On October 17, 2023, DuPont, a globally recognized leader in technology for a broad range of innovations in medical devices, biopharmaceutical processing, and pharmaceutical solutions launched Liveo™ MG 7-9960 Soft Skin Adhesive. ...
Read More...
Oct 18, 2023
Allergy Diagnostics: Unraveling the Science, Market Trends, and Future Prospects
Allergies are on the rise globally, affecting millions of people and significantly impacting their quality of life. The ability to accurately diagnose and manage allergies is crucial for both patients and healthcare providers. With the rising prevalence of allergy, the demand for Allergy Diagnostics has increased m...
Read More...